Companies: 10,795·Total market cap: $144.5T
Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc.

PTIXNASDAQHealthcare● Active
$0.50
$-0.03(-5.66%)
Market Cap$905104
P/E Ratio—
52W High$6.2
52W Low$0.25
Insider TradesOwnershipEmployees

Protagenic Therapeutics, Inc. (PTIX) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · PTIX · as of Jun 9, 2026

Activity summary

Buy transactions

2

P-Purchase only

Sell transactions

1

12 Months

Buy/Sell ratio

2.00

Buy/Sell (by trades)

Overall sentiment

BULLISH
↑ Buy 67%Active transactions only · RSU vesting excluded33% Sell ↓

Protagenic Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

PTIX insider buying and selling by quarter

PTIX insider selling · PTIX insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling
586K293K0
2006 Q4
2022 Q2
2023 Q4

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Recent insider transactions

PTIX executive sell shares · PTIX board member insider trading · PTIX insider trading SEC filing

Showing 5 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

ARMEN GARO H

See Remarks · Director

Purchase

Date

Jun 17

Shares

60,211

Price

$1.25

Value

$75K

View Form 4 on SEC.gov

MUSCI RAYMOND

Exec VP, Corporate Development · Director

Purchase

Date

Dec 13

Shares

1,758

Price

$2.09

Value

$4K

View Form 4 on SEC.gov

MUSCI RAYMOND

Exec VP, Corporate Development · Director

Purchase

Date

Dec 13

Shares

300

Price

$2.08

Value

$624

View Form 4 on SEC.gov

MUSCI RAYMOND

Exec VP, Corporate Development · Director

Purchase

Date

Dec 13

Shares

569

Price

$2.07

Value

$1K

View Form 4 on SEC.gov

MUSCI RAYMOND

Exec VP, Corporate Development · Director

Purchase

Date

Dec 13

Shares

74

Price

$2.00

Value

$148

View Form 4 on SEC.gov

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About PTIX insider trading

PTIX insider trades

Protagenic Therapeutics, Inc. (PTIX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including PTIX. Over the past 12 months, 0 insiders have filed transactions with the SEC. PTIX insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Protagenic Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic
acquisitionOrDisposition field:
A = Acquisition (buy) · D = Disposition (sell)
RSU vesting (M-Exempt) excluded from sentiment
Form 4SEC filing required within 2 business days of any insider transaction
10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot
Open MktDirect purchase or sale on the open market (excludes awards, options)
OwnershipSEC filingsFinancial statementsPrice historyForecast & ratingsEarnings

Frequently asked questions

PTIX insider trading · 5 questions

The insiders of Protagenic Therapeutics, Inc. (PTIX) include executives and directors such as PTIX, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

PTIX board member insider tradingwho are PTIX insidersPTIX insider rosterProtagenic Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026